Business Context and Reporting Period
Company: Autonomix Medical, Inc. (AMIX)
Filing Type: Form 8-K (Current Report)
Date of Report: July 21, 2025
Event: Entry into a Material Definitive Agreement regarding a warrant exercise inducement offer.
Key Financial Metrics and Transaction Details
This filing details a capital raise transaction rather than standard operating financial results. Key metrics include:
- Expected Gross Proceeds: Approximately $2.5 million from the exercise and prepayment of existing warrants.
- Shares Underlying Existing Warrants: 1,477,596 shares.
- Reduced Exercise Price: $1.723 per share for the majority of warrants.
- Prepayment Terms: Holders agreed to prepay $1.722 per share for 622,596 shares to secure a further price reduction to $0.001 per share for those specific shares.
- Placement Agent Fees: 8.0% cash fee of aggregate gross proceeds plus a warrant for 6.0% of shares underlying the existing warrants.
- Post-Transaction Share Count: 4,877,625 shares of common stock outstanding.
Material Changes and New Agreements
The Company entered into an Inducement Letter with holders of warrants issued in November 2024. Material changes include:
- Price Reduction: Exercise price of existing warrants reduced to $1.723 per share.
- New Warrant Issuance: Issuance of new Series B "Inducement Warrants" to purchase up to 1,477,596 shares (100% of the underlying existing warrant shares).
- Inducement Warrant Terms:
- Exercise Price: $1.723 per share.
- Term: 5.5 years from the initial exercise date.
- Beneficial Ownership Limitation: Exercise capped at 4.99% or 9.99% of outstanding shares at holder election.
- Registration Obligation: Company must file a resale registration statement by August 20, 2025, and seek effectiveness within 180 days.
Outlook, Risks, and Contingencies
Management Commentary and Outlook: The transaction is designed to secure immediate capital and extend the warrant term. The Company anticipates receiving proceeds prior to fee deductions.
Risks and Contingencies:
- Registration Risk: The Inducement Warrants may only be exercised on a cashless basis if a registration statement is not effective six months after issuance.
- Dilution: The issuance of new warrants and the exercise of existing warrants will increase the total share count to 4,877,625.
- Legal Disclaimer: Representations in the Inducement Letter are for risk allocation between parties and not statements of fact for investors; standards of materiality may differ from investor perspectives.
- Unregistered Securities: Inducement Warrants are issued under Section 4(a)(2) exemption and cannot be sold in the U.S. absent registration or exemption.
Investor Verification Checklist
- Verify the effectiveness of the Resale Registration Statement by August 20, 2025, to ensure Inducement Warrants can be exercised for cash.
- Confirm the final net proceeds after deducting the 8.0% placement agent fee and other expenses.
- Monitor the Company's cash burn rate relative to the $2.5 million expected proceeds to assess runway extension.
- Review the impact of the increased share count (4,877,625) on earnings per share and potential future dilution from the new 5.5-year warrants.
- Check for any subsequent filings regarding the "Beneficial Ownership Limitation" elections by holders.